Mai H. S. Mohammad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mai H. S. Mohammad has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Omran
Department of Pediatrics & Neonatology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
2 shared publications - Eman Ali Toraih
Department of Cardiovascular Perfusion, College of Health Professions, Upstate Medical University, New York, NY 13210, USA
2 shared publications Abdallah Maaroof
Suez Canal University, Faculty of Medicine, Departments of Pediatrics & Neonatology, Ismailia, Egypt
1 shared publicationAmal Fathy
A Clinical Pathology Department, Faculty of Medicine , Suez Canal University , Ismailia , Egypt
1 shared publicationAmina Abdelwahab
Suez Canal University, Faculty of Medicine, Departments of Pediatrics & Neonatology, Ismailia, Egypt
1 shared publication- Eida Mohammed Alshammari
Department of Chemistry, College of Sciences, University of Ha’il, Ha’il 2440, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 30 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 5095
Association of microRNA-34a rs2666433 (A/G) Variant with Systemic Lupus Erythematosus in Female Patients: A Case-Control Study
Several microRNAs (miRNAs) are associated with autoimmune disease susceptibility and phenotype, including systemic lupus erythematosus (SLE). We aimed to explore for the first time the role of the miRNA-34a gene (MIR34A) rs2666433A > G variant in SLE risk and severity. A total of 163 adult patients with SLE and matched controls were recruited. Real-Time allelic discrimination PCR was applied for genotyping. Correlation with disease activity and clinic-laboratory data was done. The rs2666433 variant conferred protection against SLE development under heterozygous [A/G vs. G/G; OR = 0.57, 95%CI = 0.34–0.95], homozygous [A/A vs. G/G; OR = 0.52, 95%CI = 0.29–0.94], dominant [A/G + A/A vs. GG; OR = 0.55, 95%CI = 0.35–0.88], and log-additive [OR = 0.71, 95%CI = 0.53–0.95] models. Data stratification by sex revealed a significant association with SLE development in female participants under heterozygous/homozygous models (p-interaction = 0.004). There was no clear demarcation between SLE patients carrying different genotypes regarding the disease activity index or patients stratified according to lupus nephritis. Enrichment analysis confirmed the implication of MIR34A in the SLE pathway by targeting several genes related to SLE etiopathology. In conclusion, although the MIR34A rs2666433 variant conferred protection against developing SLE disease in the study population, it showed no association with disease activity. Replication studies in other populations are warranted.
- 30 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 5095
Open AccessAssociation of microRNA-34a rs2666433 (A/G) Variant with Systemic Lupus Erythematosus in Female Patients: A Case-Control Study
Several microRNAs (miRNAs) are associated with autoimmune disease susceptibility and phenotype, including systemic lupus erythematosus (SLE). We aimed to explore for the first time the role of the miRNA-34a gene (MIR34A) rs2666433A > G variant in SLE risk and severity. A total of 163 adult patients with SLE and matched controls were recruited. Real-Time allelic discrimination PCR was applied for genotyping. Correlation with disease activity and clinic-laboratory data was done. The rs2666433 variant conferred protection against SLE development under heterozygous [A/G vs. G/G; OR = 0.57, 95%CI = 0.34–0.95], homozygous [A/A vs. G/G; OR = 0.52, 95%CI = 0.29–0.94], dominant [A/G + A/A vs. GG; OR = 0.55, 95%CI = 0.35–0.88], and log-additive [OR = 0.71, 95%CI = 0.53–0.95] models. Data stratification by sex revealed a significant association with SLE development in female participants under heterozygous/homozygous models (p-interaction = 0.004). There was no clear demarcation between SLE patients carrying different genotypes regarding the disease activity index or patients stratified according to lupus nephritis. Enrichment analysis confirmed the implication of MIR34A in the SLE pathway by targeting several genes related to SLE etiopathology. In conclusion, although the MIR34A rs2666433 variant conferred protection against developing SLE disease in the study population, it showed no association with disease activity. Replication studies in other populations are warranted.
- 17 November 2018
- Published by Taylor & Francis in Autoimmunity
- Vol. 51 (8) , 378-385
IL-37 gene variant (rs3811047): A marker of disease activity in rheumatoid arthritis: A pilot study
Background: Rheumatoid arthritis (RA) is a joint destructive disorder with great morbidity. Unraveling genetic determinants causing the disease would pave the road towards early detection and precise medicine. Interleukin 37 (IL-37), a natural inhibitor of innate immunity, was shown to be a key modulator in RA. Plasma levels were deregulated and correlated with disease activity. Therefore, we hypothesized the IL-37 gene variants could influence the clinical characteristics of RA patients. Objective: This is a pilot study to assess the association of rs3811047 variant of IL-37 gene with RA development and disease activity in an Egyptian population. Methods: A total of 100 individuals (50 RA patients and 50 healthy individuals) were enrolled in the study. Disease activity score of 28 joints (DAS28) was estimated for RA patients. Genotyping was performed using Real-Time PCR technology. Results: There was no statistically significant association between genotype frequencies of rs3811047 and RA risk. However, there was a significant relationship between the studied single nucleotide polymorphism (SNP) and disease activity. Patients carrying the GG genotype had higher DAS28 score than patients with AA or AG genotypes (p = .041). Conclusion: IL-37 gene rs3811047 SNP was associated with more severe RA disease activity in the current population. Larger epidemiological study is warranted to validate our results.
- 17 November 2018
- Published by Taylor & Francis in Autoimmunity
- Vol. 51 (8) , 378-385
IL-37 gene variant (rs3811047): A marker of disease activity in rheumatoid arthritis: A pilot study
Background: Rheumatoid arthritis (RA) is a joint destructive disorder with great morbidity. Unraveling genetic determinants causing the disease would pave the road towards early detection and precise medicine. Interleukin 37 (IL-37), a natural inhibitor of innate immunity, was shown to be a key modulator in RA. Plasma levels were deregulated and correlated with disease activity. Therefore, we hypothesized the IL-37 gene variants could influence the clinical characteristics of RA patients. Objective: This is a pilot study to assess the association of rs3811047 variant of IL-37 gene with RA development and disease activity in an Egyptian population. Methods: A total of 100 individuals (50 RA patients and 50 healthy individuals) were enrolled in the study. Disease activity score of 28 joints (DAS28) was estimated for RA patients. Genotyping was performed using Real-Time PCR technology. Results: There was no statistically significant association between genotype frequencies of rs3811047 and RA risk. However, there was a significant relationship between the studied single nucleotide polymorphism (SNP) and disease activity. Patients carrying the GG genotype had higher DAS28 score than patients with AA or AG genotypes (p = .041). Conclusion: IL-37 gene rs3811047 SNP was associated with more severe RA disease activity in the current population. Larger epidemiological study is warranted to validate our results.
- Open Access
- 1 January 2018
- Published by Elsevier in Jornal de Pediatria
- Vol. 94 (1) , 82-87
Salivary C-reactive protein, mean platelet volume and neutrophil lymphocyte ratio as diagnostic markers for neonatal sepsis
- 1 January 2018
- Published by Elsevier in Jornal de Pediatria
- Vol. 94 (1) , 82-87
Open AccessSalivary C-reactive protein, mean platelet volume and neutrophil lymphocyte ratio as diagnostic markers for neonatal sepsis
- 16 November 2017
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 12 (4) , 1644-1650
Salivary C‐reactive protein and mean platelet volume in diagnosis of late‐onset neonatal pneumonia
Background: Neonatal pneumonia is an important and major cause of neonatal morbidity and mortality worldwide therefore; its early detection plays a crucial role in successful therapy. Analysis of saliva as a non‐invasive method for detection of neonatal diseases holds great promise for improving health care. Till now, salivary C‐reactive protein (CRP), mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelets/lymphocytes ratio (PLR) have not been studied as markers of diagnosis in neonatal pneumonia.Objective: To assess the applicability of salivary CRP, MPV, NLR and PLR as diagnostic markers in late‐onset neonatal pneumonia.Methods: A prospective case control study of 70 full‐term neonates, 35 with late‐onset neonatal pneumonia and 35 healthy controls, was enrolled. Serum and salivary CRP concentrations were measured by ELISA, while MPV, NLR and PLR were measured by automated blood cell counter.Results: This study showed a statistically significant difference between salivary CRP means in neonates with late‐onset neonatal pneumonia vs control neonates (6.2 ± 4.6 and 2.8 ± 1.9 ng/L) respectively. At the cutoff point of 3.8 ng/L, salivary CRP showed 91.4% sensitivity and 80.9% specificity. Salivary CRP also showed accuracy in predicting elevated serum CRP in neonates with pneumonia. MPV showed a significant difference between pneumonia and controls (mean = 10.2 ± 0.7, 8 ± 0.5) respectively. At cutoff point 9.0, it has 80% sensitivity and specificity.Conclusions: The present study showed for the first time that both salivary CRP and MPV are suitable as diagnostic markers in late‐onset neonatal pneumonia.
- 16 November 2017
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 12 (4) , 1644-1650
Salivary C‐reactive protein and mean platelet volume in diagnosis of late‐onset neonatal pneumonia
Background: Neonatal pneumonia is an important and major cause of neonatal morbidity and mortality worldwide therefore; its early detection plays a crucial role in successful therapy. Analysis of saliva as a non‐invasive method for detection of neonatal diseases holds great promise for improving health care. Till now, salivary C‐reactive protein (CRP), mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelets/lymphocytes ratio (PLR) have not been studied as markers of diagnosis in neonatal pneumonia.Objective: To assess the applicability of salivary CRP, MPV, NLR and PLR as diagnostic markers in late‐onset neonatal pneumonia.Methods: A prospective case control study of 70 full‐term neonates, 35 with late‐onset neonatal pneumonia and 35 healthy controls, was enrolled. Serum and salivary CRP concentrations were measured by ELISA, while MPV, NLR and PLR were measured by automated blood cell counter.Results: This study showed a statistically significant difference between salivary CRP means in neonates with late‐onset neonatal pneumonia vs control neonates (6.2 ± 4.6 and 2.8 ± 1.9 ng/L) respectively. At the cutoff point of 3.8 ng/L, salivary CRP showed 91.4% sensitivity and 80.9% specificity. Salivary CRP also showed accuracy in predicting elevated serum CRP in neonates with pneumonia. MPV showed a significant difference between pneumonia and controls (mean = 10.2 ± 0.7, 8 ± 0.5) respectively. At cutoff point 9.0, it has 80% sensitivity and specificity.Conclusions: The present study showed for the first time that both salivary CRP and MPV are suitable as diagnostic markers in late‐onset neonatal pneumonia.
- 13 January 2014
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biomarkers
- Vol. 4 (1) , 11-20
Cytokines Polymorphism and mRNA Expression as Biomarkers in HCV Treatment Response
Background: Hepatitis C virus is a serious global health problem affecting more than 170 million patients who are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Egypt has the highest prevalence of HCV (genotype 4) as about 14.7% of Egyptian populations are positive for HCV antibodies. Aim: To review recent data and patents concerning cytokine polymorphism that affect the likelihood of achieving SVR and can be used as biomarkers for predicting the treatment response to overcome the unnecessary cost, time, and side effects of antiviral therapy for nonresponders. Methods: Data were pooled from 36 studies carried out internationally in which patients with chronic HCV receiving PEG IFN/RBV therapy were evaluated regarding cytokine polymorphism and/or its mRNA expression profile in relation to therapy response. Results and Conclusions: Studies to date have shown that cytokine gene polymorphism plays an important role in the natural clearance of HCV. Most of polymorphisms are in cytokine gene regulatory regions and are consequently involved directly in controlling the transcription rates. Type 1-like cytokines, such as IL-1β, IL-2, IL-6, IL-18, TNF-α, and IFN-γ were up-regulated in chronic HCV infection. The poor response was found to be associated with high producing genotype of IL-10, up-regulation of IL-28B and most of IGS genes, and associated with downregulation of TGF- β, IFN-γ. Good response was noticed to be associated with high level IL-6, IL-8, and certain genotypes of IL-6, IL-12, IFN-γ, TNF-α IFN λ4 and IFN λ3.
- 13 January 2014
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biomarkers
- Vol. 4 (1) , 11-20
Cytokines Polymorphism and mRNA Expression as Biomarkers in HCV Treatment Response
Background: Hepatitis C virus is a serious global health problem affecting more than 170 million patients who are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Egypt has the highest prevalence of HCV (genotype 4) as about 14.7% of Egyptian populations are positive for HCV antibodies. Aim: To review recent data and patents concerning cytokine polymorphism that affect the likelihood of achieving SVR and can be used as biomarkers for predicting the treatment response to overcome the unnecessary cost, time, and side effects of antiviral therapy for nonresponders. Methods: Data were pooled from 36 studies carried out internationally in which patients with chronic HCV receiving PEG IFN/RBV therapy were evaluated regarding cytokine polymorphism and/or its mRNA expression profile in relation to therapy response. Results and Conclusions: Studies to date have shown that cytokine gene polymorphism plays an important role in the natural clearance of HCV. Most of polymorphisms are in cytokine gene regulatory regions and are consequently involved directly in controlling the transcription rates. Type 1-like cytokines, such as IL-1β, IL-2, IL-6, IL-18, TNF-α, and IFN-γ were up-regulated in chronic HCV infection. The poor response was found to be associated with high producing genotype of IL-10, up-regulation of IL-28B and most of IGS genes, and associated with downregulation of TGF- β, IFN-γ. Good response was noticed to be associated with high level IL-6, IL-8, and certain genotypes of IL-6, IL-12, IFN-γ, TNF-α IFN λ4 and IFN λ3.